Breast cancer: a new treatment for hope tested at the ICM-Val d’Aurelle in Montpellier

Presented at the ASCCO (American Society of Clinical Oncology) Conference, Annual World Meeting of Oncology in Chicago, June 2-6, the Destiny Breast study shows the main interest of a molecule, Trastuzumab Deuxtecan, with very encouraging results in 557 women with metastatic breast cancer. . Sixteen patients, the largest group of study centers worldwide, were recruited to the ICM Val d’Aurelle in Montpellier, in a protocol led by Professor William Jacot, second author of a scientific article published in the New England Journal of Medicine.

Applause: Presentation of the “Destiny Chest” study that tests the usefulness of the molecule Trastuzumab Deuxtecan against breast cancer was very well received, a few days ago, at a plenary session at the ASCO (American Society of Clinical Oncology) conference, the World Summit on Oncology.

Double news: The International Medical Center in Montpellier is the center with the largest number of patients in the world (16 out of 557), and Professor William Jacot is the second author of a scientific article from the “Destiny Breast” study, published in New England Journal of Medicine, “Paris Match” Oncology, Doctor’s Slips.

Why all this enthusiasm?

Trastuzumab Deuxtecan is an ‘antibody conjugated’, ADC for specialists, which combines, by simplification, antibodies and a chemotherapy drug to target only cancer cells, and is therefore less toxic than ‘classic’ chemotherapy. It was not known to oncologists that it was used until now to treat a specific type of breast cancer, when biological analysis showed an overexpression of the HER2 protein, naturally present in the body, which increases sharply to promote the growth of cancer cells.

“We used trastuzumab when HER2 is highly overexpressed, that is, 15% of cancers. Our idea was to use it when HER2 is poorly expressed, that is, approximately 50% of women with metastatic breast cancer”, says Professor Jacot, who, like his colleagues, recruited volunteer patients for this second stage among those who had cancer with metastases, with a very poor prognosis. “They have exhausted all treatment avenues. 16 women entered the study in 2018, such as Emmanuel, who testified in favor of Medilibre.

“It’s one of the greatest stories of this adventure.”says the doctor. after that day Most of these women are alive.. The study was conducted double-blind, and compared two groups: women who received conventional chemotherapy, and others who received chemotherapy “grafted” on the antibody. consequences : “The average life expectancy of patients increases by six months”. “The last time we made progress with a new treatment for breast cancer, we got two months older, which is very encouraging.”Greetings Professor Jacot.

A new study has begun with the same molecule taken this time in early-stage breast cancer. He hopes this will show that patient survival can be improved even further. Each year, in France, 60,000 new cases of breast cancer are diagnosed, and 12,000 in the stage of metastases, associated with a life expectancy of five years. “There is still a long way to go, but as oncology slowly progresses, we are taking a huge step here. These findings give hope to 6000 women”William Jacot concludes. And the “All efforts in clinical research are justified.”

Emmanuel, 50: “This molecule saved my life”

At 42, Emmanuel was diagnosed with breast cancer. The discovery is late, the young woman had liver metastases. Treatment combines surgery (mastectomy), chemotherapy and radiotherapy. “I had a moment of remission, and then new tumors in the liver re-emerged,” explains Emmanuel, 50 today, who participated in the clinical trial after treatment with hormone therapy. For the past two years, she’s been going to the International Center for Midwives every three months to continue chemotherapy, which is now effective. “I had migraines in the first month, hair loss, and a lot of fatigue. Today, I am almost back to normal, and I hope to be back at work in September after two years of sick leave,” she explains, with Sarah’s news: The scan done three weeks ago showed no worrying signs, now we have to move on, this molecule saved my life.”

Leave a Comment